Rheumatoid Arthritis

Methotrexate is considered first-line therapy for rheumatoid arthritis, but if this fails to control symptoms, it is time to consider a second-line therapy. TNF inhibitors and IL inhibitors are options, but which to choose? Learn more in this quiz.

Patients with rheumatic disease are at higher risk for skin cancer, gastrointestinal infectious, pulmonary disease, and hematologic conditions. A new study finds that taking low-dose methotrexate may lower the risk of developing these conditions.

Rheumatoid arthritis is not associated with an increased risk of death in patients hospitalized for pneumonia, unless it is uncontrolled, shows a new study.

Rheumatoid arthritis patients have nearly a double risk of atherosclerotic CVD, stroke, heart failure and atrial fibrillation, but they receive poorer primary and secondary preventive care than other high-risk patients. Learn more in this summary of a review published in Nature Reviews Rheumatology.

The mosquito-borne chikungunya virus can lead to symptoms of arthritis that are similar to rheumatoid arthritis. In this Q&A, we speak with the an expert who recently published a review article focusing on the commonalities between the two conditions.

Rheumatoid arthritis is not a life threatening condition per se, but it can have a dramatic impact on life expectancy. As a chronic systemic inflammatory condition, rheumatoid arthritis increases the risk of a number of other leading causes of death. Are you familiar with mortality risk in RA? Take this quiz.

In today's news roundup, we feature a discussion with Ben Nowell, Ph.D., director of Patient Centered Research for the Global Healthy Living Foundation, which five years ago launched ArthritisPower, a mobile app used in healthcare research. Learn more in this interview.

There are many treatments and strategies to address fatigue in rheumatoid arthritis (RA) patients, but no one approach works for all patients. In this slideshow, we highlight key takeaways from a recent review that highlights key strategies for treating fatigue in RA.

Rheumatoid arthritis patients receive treatment that is on par with that of a physician, shows a study based on patient-reported outcomes and disease activity. The study was recently reported at the EULAR annual meeting.

Insulin resistance is independently associated with body mass index and synovitis in rheumatoid arthritis patients, shows new research published in Arthritis and Rheumatology.

Researchers report that methotrexate with a tumor necrosis factor inhibitor may be best for biologic naive rheumatoid arthritis patients.

Rheumatologists should feel more confident in recommending vaccination against herpes zoster to patients with rheumatoid arthritis after a study suggested that the recently approved recombinant adjuvanted vaccine was well tolerated in this group of patients.

One in a 100 rheumatoid arthritis patients with high disease activity will develop a venous thromboembolism, a more than twofold increase compared to patients in remission, according to results from a Swedish cohort study presented at the European Congress of Rheumatology (EULAR) annual meeting last week.

The drug is well-tolerated in methotrexate inadequate response patients with rheumatoid arthritis.

Patients who cannot tolerate cDMARDs may experience additional value from tocilizumab compared to adalimumab.

Rheumatoid arthritis patients with probably major depressive disorder or generalized anxiety disorder were more likely to suffer from worse fatigue and pain.

A team investigated data from trials of tofacitinib, adalimumab, and placebo.

The safety profile of upadacitinib is consistent with phase 3 rheumatoid arthritis studies.

The incidence rate of serious infection events and opportunistic infections was higher among the upadacitinib 30 mg group than the 15 mg group.

In a late-breaking abstract, investigators test nanoparticle treatment using in vivo models.

The findings are important to understand treatment persistence and switch patterns in rheumatoid arthritis patients with poor prognostic factors in a real-world setting.

The results highlight a significant improvement in rheumatoid arthritis signs and symptoms for those who used upadacitinib over placebo and adalimumab.

In a study presented at EULAR, investigators find 14-3-3η baseline levels did not correlate with baseline mTSS.

Patients are unaffected by the switch from ADL-EU to ADL-PF.

Researchers writing in Arthritis and Rheumatology report that high levels of anti-citrullinated protein antibodies (anti-CCP2) appear to be markers for future cardiovascular events in rheumatoid arthritis patients.